Escherichia Abundance and Metabolism Align with Vitiligo Disease Activity
Mukhatayev Z. Kovenskiy A. Ren Z. Rangel S.M. Katkenov N. Khuanbai Y. Shivde R. Daniel M. Dellacecca E.R. Cedercreutz K. Ostapchuk Y. Nurgozhina A. Chulenbayeva L. Nurgaziyev M. Jarmukhanov Z. Nurlankyzy M. Kozhdan K. Seidulla S. Mukhanbetzhanova Z. Sergazy S. Kozhakhmetov S. Ali Y. Daftary K.M. Green S.J. Kundu R.V. Kushugulova A. Le Poole I.C.
September 2025Elsevier B.V.
Journal of Investigative Dermatology
2025#145Issue 92236 - 2250.e1 pp.
Vitiligo is a cutaneous autoimmune disorder characterized by progressive depigmentation due to melanocyte destruction by cytotoxic T cells. Genetic factors predispose patients to the disease and are supported by environmental factors that often initiate new disease episodes. We investigated whether disease outcomes were partially defined by pathogenic microbes that drive nutrient deficiency and inflammation. Our study presents the results of research on the diet and gut microbiome composition of patients with vitiligo and healthy controls from Kazakhstan and the United States. Dietary nutrient intake was assessed using the National Institutes of Health–generated Diet History Questionnaire. Patients with active vitiligo exhibit a limited intake of specific fatty acids, amino acids, fiber, and zinc. Disease activity was further characterized by the abundance of Odoribacter and Escherichia in the gut. Metabolic pathway analysis supported the role of the Escherichia genus in disease activity by limiting energy metabolism and amino acid biosynthetic pathways. Disease activity also aligned with elevated circulating pro-inflammatory cytokines. These findings suggest that nutritional limitations are not compensated by metabolites from the gut microbiome in active disease, potentially leaving room for inflammation and exacerbating vitiligo. The intricate relationship among diet, gut microbiome composition, and disease progression in vitiligo highlights potential avenues for targeted interventions to reduce autoimmune activity and improve patient outcomes.
Autoimmunity , Immunology , Microbiome , Vitiligo
Text of the article Перейти на текст статьи
National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
Temprian Therapeutics, Chicago, IL, United States
Almaty Branch of the National Center for Biotechnology, Almaty, Kazakhstan
Genomics and Microbiome Core Facility, Rush University, Chicago, IL, United States
National Laboratory Astana
Department of Dermatology
Temprian Therapeutics
Almaty Branch of the National Center for Biotechnology
Genomics and Microbiome Core Facility
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026